Universidad Peruana Cayetano Heredia

Cysticercosis of the central nervous system: How should it be managed?

Mostrar el registro sencillo del ítem

dc.contributor.author García Lescano, Héctor Hugo
dc.contributor.author Gonzalez Zariquiey, Armando Emiliano
dc.contributor.author Gilman, Robert Hugh
dc.date.accessioned 2022-01-18T19:26:52Z
dc.date.available 2022-01-18T19:26:52Z
dc.date.issued 2011
dc.identifier.uri https://hdl.handle.net/20.500.12866/10963
dc.description.abstract Purpose of Review: Taenia solium neurocysticercosis (NCC) has been long recognized as an important cause of neurological morbidity in most of the world. Unwarranted generalization of diagnostic and treatment recommendations made it difficult to assess individual prognosis and responses for each type of NCC. Understanding of the main clinical presentations (dependent on number, location, size, and stage of parasites, as well as on the immune response of the host) allows a better view of treatment options and expected outcomes. Recent Findings: Current treatment options are still limited and involve symptomatic agents, antiparasitic agents, or surgery. The importance of adequate symptomatic management, the potential for improved antiparasitic treatment regimes, in particular combination therapy, and the increasingly important role of minimally invasive neurosurgery are also reviewed in this article. Summary: Treatment decisions in NCC should be individualized in relation to the type of NCC. Initial measures should focus on the symptomatic management before considering antiparasitic therapy when appropriate. Appropriate patient categorization, new antiparasitic regimes, and minimally invasive surgery are improving the prognosis of patients with NCC. en_US
dc.language.iso eng
dc.publisher Wolters Kluwer Health
dc.relation.ispartofseries Current Opinion in Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans|Review en_US
dc.subject Prognosis en_US
dc.subject Treatment en_US
dc.subject Disease Models |Albendazole en_US
dc.subject Outcome Assessment en_US
dc.subject Computer Assisted Tomography en_US
dc.subject Taenia Solium en_US
dc.subject Taeniasis en_US
dc.subject Cysticercosis en_US
dc.subject Praziquantel en_US
dc.subject Swine en_US
dc.subject Symptomatology en_US
dc.subject Pathogenesis en_US
dc.subject Immune Response en_US
dc.subject Drug Dose Increase en_US
dc.subject Anticonvulsant Therapy en_US
dc.subject Anticonvulsive Agent en_US
dc.subject Antiparasitic Agents en_US
dc.subject Extraparenchymal Neurocysticercosis en_US
dc.subject Gray Matter en_US
dc.subject Intraparenchymal Brain Cysticercosis en_US
dc.subject Minimally Invasive Surgery en_US
dc.subject Seizure en_US
dc.title Cysticercosis of the central nervous system: How should it be managed? en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1097/QCO.0b013e32834a1b20
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1473-6527


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas